心力衰竭：心力衰竭临床试验：我们如何定义成功？
Heart failure: Heart failure clinical trials: how do we define success?
机构信息
Division of Cardiology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, A2-237 CHS, Los Angeles, CA 90095-1679, USA.
出版信息
Nat Rev Cardiol. 2013 Sep;10(9):492-4. doi: 10.1038/nrcardio.2013.115. Epub 2013 Aug 6.
Abstract
The selection of end points for clinical trials of heart failure is challenging, with important implications for patients, the medical community, and regulatory agencies. The standards used in clinical research on patients with heart failure influence the effectiveness and value of future clinical trials, and the extent to which they can be translated into clinical practice.
摘要
心力衰竭临床试验终点的选择具有挑战性，对患者、医学界和监管机构都有重要影响。心力衰竭患者临床研究中使用的标准影响未来临床试验的效果和价值，以及它们在多大程度上可以转化为临床实践。
相似文献
1
Heart failure: Heart failure clinical trials: how do we define success?心力衰竭：心力衰竭临床试验：我们如何定义成功？
Nat Rev Cardiol. 2013 Sep;10(9):492-4. doi: 10.1038/nrcardio.2013.115. Epub 2013 Aug 6.
2
Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.心力衰竭临床试验的惊人愚蠢：关于研究者和指南如何权衡证据的不便真相。
Circ Heart Fail. 2016 Apr;9(4):e002837. doi: 10.1161/CIRCHEARTFAILURE.116.002837.
3
Pragmatic approaches to the next generation of clinical trials in heart failure.心力衰竭下一代临床试验的实用方法。
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):282-283. doi: 10.1093/ehjcvp/pvaa085.
4
Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward.在ST段抬高型心肌梗死试验中定义心力衰竭终点：整合过往经验以规划前进道路。
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):594-600. doi: 10.1161/CIRCOUTCOMES.112.966150.
5
Bleeding definitions in orthopaedic VTE prophylaxis trials: a real need for standardization.骨科静脉血栓栓塞症预防试验中的出血定义：标准化的迫切需求。
Thromb Res. 2012 Oct;130 Suppl 1:S32. doi: 10.1016/j.thromres.2012.08.268.
6
Developing core outcome sets for clinical trials: issues to consider.制定临床试验核心结局集：需要考虑的问题。
Trials. 2012 Aug 6;13:132. doi: 10.1186/1745-6215-13-132.
7
Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.生物标志物在心力衰竭临床试验中的既定作用与新兴作用
Circ Heart Fail. 2016 Sep;9(9). doi: 10.1161/CIRCHEARTFAILURE.115.002528.
8
The COMET Handbook: version 1.0.《COMET手册：第1.0版》
Trials. 2017 Jun 20;18(Suppl 3):280. doi: 10.1186/s13063-017-1978-4.
9
The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.临床医生作为研究者：在临床实践中参与临床试验：附录1：研究设计基础
Circulation. 2004 Jun 1;109(21):e302-4. doi: 10.1161/01.CIR.0000128807.57602.61.
10
2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS.2018年欧洲心律协会（EHRA）关于导线拔除的专家共识声明：临床科学研究和注册登记的定义、终点、研究试验设计及数据收集要求的建议：得到亚太心脏节律学会（APHRS）/美国心律学会（HRS）/拉丁美洲心脏节律学会（LAHRS）认可。
Europace. 2018 Jul 1;20(7):1217. doi: 10.1093/europace/euy050.
引用本文的文献
1
Cell Therapy Improves Quality-of-Life in Heart Failure: Outcomes From a Phase III Clinical Trial.细胞疗法改善心力衰竭患者生活质量：III 期临床试验结果。
Stem Cells Transl Med. 2024 Feb 14;13(2):116-124. doi: 10.1093/stcltm/szad078.
2
Drugs' development in acute heart failure: what went wrong?急性心力衰竭药物研发：错在哪里？
Heart Fail Rev. 2018 Sep;23(5):667-691. doi: 10.1007/s10741-018-9707-y.
本文引用的文献
1
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.心力衰竭临床试验的临床结局终点：欧洲心脏病学会心力衰竭协会共识文件。
Eur J Heart Fail. 2013 Oct;15(10):1082-94. doi: 10.1093/eurjhf/hft095. Epub 2013 Jun 19.
2
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南：美国心脏病学会基金会/美国心脏协会实践指南工作组报告
Circulation. 2013 Oct 15;128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5.
3
Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.基于利钠肽的生活质量和慢性心力衰竭治疗：来自利钠肽指导的门诊个体化慢性心力衰竭治疗（PROTECT）研究的结果。
Am Heart J. 2012 Nov;164(5):793-799.e1. doi: 10.1016/j.ahj.2012.08.015.
4
Challenges in coding adverse events in clinical trials: a systematic review.临床试验中不良事件编码的挑战：系统评价。
PLoS One. 2012;7(7):e41174. doi: 10.1371/journal.pone.0041174. Epub 2012 Jul 20.
5
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?观点：在以结果为导向的临床试验中对心肌梗死进行中心裁定——TRITON、RECORD 和 PLATO 中的常见模式？
Thromb Haemost. 2012 Sep;108(3):412-4. doi: 10.1160/TH12-04-0251. Epub 2012 Jul 26.
6
Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras.左心室收缩功能障碍性慢性心力衰竭的死亡特征和模式变化：跨治疗时代的研究。
Circ Heart Fail. 2011 Jul;4(4):396-403. doi: 10.1161/CIRCHEARTFAILURE.110.959882. Epub 2011 May 11.
7
Rehospitalizations among patients in the Medicare fee-for-service program.医疗保险按服务收费项目参保患者的再次住院情况。
N Engl J Med. 2009 Apr 2;360(14):1418-28. doi: 10.1056/NEJMsa0803563.
8
Composite outcomes in cardiovascular research: a survey of randomized trials.心血管研究中的复合结局：随机试验调查
Ann Intern Med. 2008 Nov 4;149(9):612-7. doi: 10.7326/0003-4819-149-9-200811040-00004.
9
The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention.心血管研究中复合终点的问题：主要不良心脏事件与经皮冠状动脉介入治疗的故事
J Am Coll Cardiol. 2008 Feb 19;51(7):701-7. doi: 10.1016/j.jacc.2007.10.034.
10
Systematic adjudication of myocardial infarction end-points in an international clinical trial.一项国际临床试验中心肌梗死终点的系统判定
Curr Control Trials Cardiovasc Med. 2001 Jul 17;2(4):180-186. doi: 10.1186/cvm-2-4-180.
Zotero 插件